我們已在上線！進一步了解

C4 Therapeutics

CCCC

市值 US$3.41億

2.77 USD

-0.01

0.36%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

2.76

-0.01

0.36%

1天

-0.36%

5天

-12.34%

1個月

-19.71%

3個月

-22.63%

6個月

-4.48%

今年迄今

43.52%

1年

11.69%

5年

-93.55%

10年

-89.13%

關於： C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

員工： 104

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 20%

中性 40%

負面 40%

中性

GlobeNewsWire

22 天前

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action

$C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting$

負面

Zacks Investment Research

24 天前

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.

中性

GlobeNewsWire

上個月

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting.

$C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting$

正面

Zacks Investment Research

上個月

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

負面

Zacks Investment Research

2 個月前

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.

正面

Zacks Investment Research

3 個月前

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

正面

Zacks Investment Research

3 個月前

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

中性

Seeking Alpha

4 個月前

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

負面

Zacks Investment Research

4 個月前

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

中性

GlobeNewsWire

4 個月前

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status

$C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population$

查看新聞排名

價格圖表採用Lightweight Charts™實作

C4 Therapeutics CCCC 市值 US$3.41億

新聞

C4 Therapeutics

CCCC

市值 US$3.41億